PKI - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Q2 2018 PerkinElmer Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time.

As a reminder, today's conference is being recorded. I would now like to turn the call over to Tommy Thomas, Vice President of Investor Relations. begin. may you Sir,

Tommy Thomas

and Good earnings welcome in conference Friel, Executive are Mark. and Vice second Financial Chief the the quarter Rob Officer. Officer; Chief and XXXX call. Chairman Mock, afternoon you, Senior to President and PerkinElmer call Jamey Thank With me

and press note being Investors have our section not earnings website copy be that get is may will at of a you you our live one August Please this on of webcast call XXXX. If XX, our www.perkinelmer.com. website received release, archived from the until

today. our as everyone We change, Before have our if any the any our of views we statements disclaim future update statements today's not begin, on obligation date press afternoon we need estimates our our in the those in Harbor to forward-looking rely release we views forward-looking as remind forward-looking SEC only that also of today earlier representing of Any any statements this after of even and made today. statements represent earnings so should issued Safe you outlined to in filings. as

Rob? to the During non-GAAP use financial I'm of GAAP and PerkinElmer, extent as available financial during that Friel. now measures we to Chairman our this introduce press referring measures the to to earnings non-GAAP non-GAAP attachment, provide to the Officer that most this Chief during certain in financial GAAP we to release. we of reconciliations not we reconciliation pleased A To reconciled Rob this call, call measure Executive will are promptly. is call measures. will plan the use comparable be directly an attachment

Robert F. Friel

and today. pleased strategic progress and and earnings our PerkinElmer for adjusted making forecast growth joining report I'm revenue important per second excellent Thanks, Tommy. that thank quarter, significantly share priorities. our you delivering Good above very afternoon had an against to us key

million, growing our representing expected, digits was growth second and EUROIMMUN results, to of as a XX%. reported in total by basis growth of specific the organic second businesses to on organically quarter double the each Turning quarter. XX% $XXX increasing revenue grew financial with XX%

However, overall impact rate year, quarter. XXX growth the of $X.XX, last growth strong basis an core expanding in an our Adjusted last to on year the due XX% businesses, of over immaterial versus organic EPS had margins this EUROIMMUN with to was the points second quarter increase XX.X%. operating QX

very execution successful both strong strategic growth as as fact very expansion. discuss growth, quarter experience detail, with will organic the While of attributable well our previously as are obviously this continued top that organic level both of more as we end with Jamey well in financial line communicated significant pleased the operating to breadth markets initiatives. and results margin is robust the demand, to A our

markets. Specifically, the helping accelerating new are our well are to key differentiated attractive are on customers' problems and innovative that of focus where growth more end capabilities leading our in each and tailoring services portfolio products challenging in our to end most investing solve markets

other and to progression disorders. develop contaminants customers vivo of better markets. & critical detect solutions and imaging the customer particular, in and service market. informatics new diseases, Discovery DAS, are the spanning well instrumentation, into projects Analytical clinic our Solutions to for cancers, a are to both and preclinical or sooner, are and experiencing as strong disease more PerkinElmer drugs disease accelerate understand and first to as both Turning uptake business, solutions wide pharma in help we analytical involving using researchers in applied and imaging our Scientists discover new our In insights infectious treatments to range therapies effectively, of and

and experienced as better. to test high-single-digit every analytical by instruments the expanded professional the our This our our is been side, fuel customers of our digitization food as around customers for molecule the improve data. offering to the has OneSource broad-based applications. to in from industrial strong In as offerings, leveraging world we segments race was our growth versatility toward the of Sciences how experience Life continue or growth share, increasingly analytical contaminants growth On and across one helping and service harness, very well medicine. driven Informatics environment collaborate, our services the the the and In as and trend technology of interpret pharma biotech lab space,

gives ultimately programming report, For helping analysis, example, plus across the that ability and customizable platforms, data researchers types new application different interfaces multiple to recently we built workflows on conduct from discover solution better compare therapies. introduced organizations and develop screening data and R&D a new assay review,

In and of continue EUROIMMUN EUROPattern ahead has emerging the use BIOCHIP areas On focus as grown areas are genomics the as researchers to technology accelerate technology improve improving technologies. provide and multiple the to been for as side, business the key detection are to understanding, clinicians and product of and capabilities, continuing Diagnostic growth in respective treatment, well adopting its we proprietary to have tests our first our to that by These have through lab around workflow. existing clearance With recently rate. this Diagnostics EUROIMMUN's two exciting our earlier synergies assays using FDA ability plans expanding and diagnosis, collaboration the product businesses, EUROIMMUN, to while our markets. regard, core this synergies outcomes. technologies year, our presence driving franchises with strengthening and mosaics We rapidly we of in our reproductive to in our new microscope. maintaining globe major And half historical disease between to relative we identify detection the announced service we out of to received new health EUROIMMUN, patient year offerings, diseases enable with find and the build several mid-teens regard are

leading which technical and advancing labs addition, synergies automated and instrumentation. on clinicians In testing standardize expanding will have to the the while patient in has also the menu market, been in efficiencies EUROIMMUN PerkinElmer to improve be of able antigen its fields antibody care. with on the working better EUROPattern will development, throughput microscopes,

quarter, in liquid for we nucleic acid in also the solutions in During gaps molecular handling PerkinElmer extraction the progressed diagnostic EUROIMMUN's closing using technologies.

bring these market growth high-single-digit to In emerging addition, the continued the technical development genomics, and synergies in our of health and better. working quarters. of experienced field reproductive In been together solutions in these franchises We coming core we to Diagnostic to infectious and or the developments have on arboviruses look in Tulip of EUROIMMUN expand menu diseases solutions our markets. forward of

testing capabilities We solutions our extraction as continue build from sequencing our up out workflow to ramp analysis, to next-generation our processes genetic in to as services. well aid

benefited additional strong test in of bank geographic such we Haoyuan testing demand spec from through China In also the expansion addition, expanding Africa. our area, of storage outside in our with FDA screening for we're In wins solutions evidenced recently rapidly diagnostic along that products LSD. emerging, blood in markets. screening Tulip's based This as as mass India business disorders, for or delighted received lysosomal from approval infectious rising newborn markets we announce growth from as have to by Tulip was disease well India, in

businesses, Based market the Vanadis position our acquisition the June, lower where both showed the CE-IVD non-invasive meeting system aneuploidies. at for filed testing of complete for as Society the Vanadis June, of acquisition The pre-launched reproductive Prenatal acquisition data testing going provides we sequencing, pre-implementation at kit least and next-generation Australia, clinical and Limited. during PerkinElmer is a tools single-cell NeoLSD Marking only where testing no-call cell good genetic cytogenetics workflow presented solution. in are RACE sensitivity sequencing which molecular Diagnostics six allowing to a sequencing-based applied Diagnostics. in of an We for single with innovative and screening the us International important in and closed Belgium, recent prenatal we genomics the approved market. as unique both and The on strengthens the and from our to and integrated customers we to and is play very CE-IVD LSDs. in that expect after positive, who system receive technologies RHS was to operate system of to in NIP solutions on role is the briefed solutions this were existing than good technicians genomics. is lab kit fit PerkinElmer's In Furthermore, offer approval Our reaction The company able FDA Also rate to CE-IVD very prospective genetic in one training. the of will be soon. workflow totally for health week

our an talked women accurate, ultimately access screening past, of we've is to trisomies. method of low-cost about goal the enable to have all As globally to in

with how lab operate pricing of largely the majority will health the Regarding dependent prefer reagent Vanadis reproductive the of rental be runs. consistent customers of today. pricing, adopting model the tests believe number customers our Consequently, will on we most

attractive pricing anticipate irrespective on to to the market alternatives we of However, value. very be current relative

As ramp up to year. plan XX service, solution the install operations the our we is and labs this in

as available current the seamlessly customers system to of to in begin work biochemical We then to with them world. Europe our we will convert regions Vanadis the to make other

on XXXX, back accelerating of increase the profits the revenue into progress profile incremental fueling company. meaningful making company we and first the converting summarize investments excellent the to So while growth are half to of

organic we points guidance again are for year, of the result once are our XXX a full-year included another to business, add As the our if organic revenue growth EUROIMMUN, would which rate. to rate our we growth making, excluding raising the for X% core progress confident increasing and basis

our call of year. an Jamey, $X.XX XX% financial adjusted EPS in over the than more performance this We of increasing now over to like I'd $X.XX, now $X.XX are our and guidance which last in original to increase will turn who our higher is detail. also January to cover represents year

James M. Mock

afternoon, company. of look since had good outlook meeting start to of and excited of the the everyone. XXXX. with some you for in about of part to May the weeks. second PerkinElmer X want forward our I pleasure and to and I Rob, you the for financial the optimistic joining Thanks, of be more I'm coming meeting highlights I've quarter

some provide served financial and I'll XXXX financial additional finish a our on second half other markets with our I'll end summary guidance. detail Next, metrics. and color of

by broad-based Life X%. revenue growth major all Adjusted by quarter consecutive We geographies. in Sciences in grew organic also revenue second the approximately sales, and in total Asia provide in the I see grew organic XX%. of strength approximately Turning foreign total Analytical highlighted with fundamentals of some exchange quarter, revenue approximately to XX% business very organic driven representing we will growth in served moment. a markets. second By driven the across by XX% revenue XXXX second a XX% representing and solid XX% strength pleased the our both growth revenue approximately organic color end XX% with adding the Americas. in in grew very organically quarter in end Diagnostics, continuing million regions, representing all markets. in in double-digit by growth acquisitions business results. were approximately in sales, on to Solutions, of quarters grew our the organically This quarter, additional the and continue We revenue market second and with XX% of quarter segment, to approximately tailwind encouraged in China the double-digit major of Discovery & applied represents geographies growth $XXX second the as and four In emerging businesses high-single-digit organic both healthy Europe were India.

to Moving the operating benefit including up details margins a operational XX%, our XX-basis-point were from income basis second adjusted increased prior XXX and quarter XX.X%, over operating comparable performance, period points adjusted EUROIMMUN. of the

quarter. strong and strong leverage points our basis the of during driven headwind foreign productivity. performance by Foreign expansion and in exchange, a the at exchange operational of XXX of XX was To quarter was acquisitions points net underlying basis volume

We are teams, product commodity of line efforts the our and each our driving by sourcing categories. in of savings encouraged

of XXXX meet XX to points of continue expect over points XX to our to guided the second of range expansion. half operating strong We basis basis adjusted margin improvements

million we XXXX, The income. versus operating with standards X, per restated an lowering a offsetting in quarter As adjusted and pension of costs a accounting XXXX increase operating other effectively reminder, an income. prior guidance January increase new adopted X effective have approximately in is our impact

EPS. is to As impact adjusted no there a result, net

foreign a of earnings $X.XX stronger by exchange. driven adjusted share Finally, partially unfavorable $X.XX our exceeded organic offset from $X.XX, growth, by guidance by $X.XX beat from per

Looking within business. second segments & further let's with our Discovery our drivers quarter, into the start Analytical key the Solutions for

verticals. organic Life with Our revenue growth high-single-digit applied driven revenue second by double-digit coupled in quarter the results strong market organic growth were in Sciences

strong increase. and revenue growth double genomics double-digit and up the led end organic reminder, business Asian a in and driven OneSource biotech instrument was to our revenue strength Discovery and very market driven into food market Sciences markets performance Applied Discovery growth organic was industrial, food, end Switching were imaging and by Drug Sciences' businesses. organic serves screening new Geographically, as by low in markets, Drug digits; Asian reproductive strong saw product end verticals. Europe and in by both by industrial increased organically driven products was Life organic a our health contributors driven in our the the segment. pharma XX% revenue sells high strength high-single-digit immunodiagnostics. by and was biotech teens; high-single-digit grew and As continued informatics in markets sales. growth content revenue academic business Life in environmental, government and growth the sales applied strength Diagnostics, solid pharma environmental, key a strong America

in Diagnostics in driven rapid at key organic business. the testing, Indian great Tulip by market. penetrating high make Looking diagnostics new continues additions our to strides teens the reported team growth and

sales in million in the of and disease about remain our approximately grow double remain Germany year. mid-teens growth this revenue to organic feel planned momentum they by were Geographically, revenues PerkinElmer half XXXX. testing to and XXXX, China achieving EUROIMMUN target good in Broad-based U.S. achieve the year. through with organically continue once build strong genomics We building our all U.S. the EUROIMMUN track for to again growth full We momentum $XX on across helped the on on first and states business

the we working with forward significant population. market opportunity that new for cost the European deliver unique to mentioned, We and Rob to look strong NIPT we product and patient a As report Vanadis provides a are we pleased relationships our penetrate offerings customer to and to that submitted to bring Mark increased market. our believe global have position to CE help technology customers larger approval, this

the at adjusted for interest net approximately tax Looking the second line rate below our XX%. approximately quarter expense was and million, was items, other adjusted and $XX

profits Looking see foreign tax driven by the at increased ahead, full in adjusted XX% rate rate now we lower year jurisdictions.

a EBITDA we and sheet, track balance X X.X debt $X debt net cash. we quarter the of quarter to times. the approximately of Turning with to finish the finished We below of $XXX and adjusted approximately million billion to ratio exited on the times, year with remain

to continuing performance, China flow Turning builds cash half supporting XXXX. impacted production coupled quarter our our inventory stronger improvement. second localization, sequential with Singapore increase in our to moves flow of Higher supporting cash operating from the operations saw demand, first and further production a manufacturing levels

reducing center have distribution orders we addition, a fulfill In strategy to new also while taken better customer logistics costs. on

with board commitment. place repurchase in have million recently our also plans and second quarter, We adjusted up free I wrap To authorization. cash our strong approved full resulted has growth share we expired new deliver our authorization, that $XXX margin organic note the in are which two-year expansion. to on flow double-digit year recently a revenue would the performance, replacing operating very pleased

continued second XXXX, Looking of ahead we XXX X%. raising solid core which provide Driven growth performance, the XXXX points. once our stakeholders. to the This strong basis to believe add organic to financial revenue half revenue again growth will are results by to half well-positioned strong we drive key for first our EUROIMMUN, that excludes and guidance organic full year are increase another we

be $X.XX Diagnostics million with of X% sales the growth now $XX foreign and debt. growth growth revenue approximately organic the million. year incorporates which organic in revenue tailwinds to now reported We assumes EUROIMMUN and to rate EUROIMMUN in billion, revenue organic approximately guidance Our of for $XXX expect exchange X% growth increasing core X% approximately

represents adjusted flowing and full second are EPS up earnings headwind. year share $X.XX through $X.XX exchange the fee XXXX. approximately versus We incremental despite This to per net XX% quarter adjusted growth our foreign taking EPS adjusted an

quarter XX% million, reported growth forecasting are prior reported third we versus revenues period. XXXX, the of the For $XXX representing of comparable revenue

foreign growth from impact on organic negligible guidance a X% from mid-teens and EUROIMMUN, basis. year-over-year core Our assumes growth, currency

per In quarter, third to we my terms Operator, time adjusted the forecasting open guidance, comparable concludes are versus for XX% up at the prepared remarks. call would $X.XX growth of we earnings share represents prior period. the which this like for questions. This

Operator

Thank you. Steve question And Stanley. of Beuchaw first our comes the from of line Morgan

line Your is now open.

Steve Beuchaw

I'd is to for have you first put its And more thing I much Hi, of the perspective for a rank the and thanks maybe unpack layer Good than sales execution the us I'd gave on did big order a new big the products? a lot on after And Jamey. I the for could you in detail a commercial little force really up the this on Any Rob, of help. afternoon. much good help on how about could How more quarter up? much of high-five but the market Corbett, if three call. this like quarter there us is end would DAS. could How step give this here restructuring? more really wonder step-up, in, growth, and product really between to Welcome, stride hitting you that's think, here it any bit best depth more I year about. talk drivers, franchise, again years. time wonder if DAS surge you you

Robert F. Friel

of on would of say things I about. it's instrument informatics saw quarter, instruments the think out. it's beat consumables, on above, came I talked all pointed of the in delta first say, the Well, good clearly as We would the you in Yeah. first largely strength we side. all, and combination I it about of all, you think and came if really side, but the and the a service

clearly So, seeing of all, execution. first I think better we're

go But now of you think is back the sales as of there. we on we've We, aided recall, the Informatics. really account businesses bit you back, selling sort which I experienced customer combined got coupled the If little the XXXX. focused with force, the OneSource solutions, initiative, in disruption complete a global by and

think going I that's So, well.

the the are continue XXXX. the on XXXX only the not QSight see strong side, in Avio, adding introduced growth new uptake strong think the we strong in we innovation from like on products but the products Things all that continued I NexION, to growth.

the On imaging content the well. did vivo both imaging in clearly side, quite Life Science area, high and our in

And in of it's And I sort look the was it so then, what broad alluded across based. comments, you strong to well. the even fairly as geography, if quite

So, clearly better execution. it's I think

we've robust. think as it's the fairly think, in continue I weeks, the And to innovation. of last I be couple think heard I markets

Steve Beuchaw

that. appreciate Really

think give The that about that second touch labs we again. as and Vanadis. appropriate. I thing where if series real in near a that the target you Mark of should revenue how I us can days, have existing you from think on sounds is success And early CE are a threads are. the you'd Vanadis transition common XXXX, the wanted PerkinElmer term the a in the you have Thank like you It driver? types sense accounts. to with customers. of the Are hopefully, to here These you think for as characterize wonder here timing, regions

Robert F. Friel

past, marking, have think I biochemical focus probably talked this first but in our X.X with do in pregnancies we So initially. CE-IVD I'd all, we Europe be the million with screening. that largely today we've of will And obviously, the say, about

getting we biochemical that of until as into probably already will to remaining that ultimately, XXXX. tests and remarks, ramp to production, obviously, those not are to I we'll all, systems mentioned part sort areas focus And of say expand – regions. of in accounts I targeted that initially, expand XXXX, those would we've Europe, XX if labs not up today the looking look with geographic as sort other throughout look and to identified the be be convert, then across then, my effectively we'll will doing to in So, that regard on Vanadis. the screening the

Operator

of Thank Dan Arias our of you. question the next comes Citigroup. And line from

line open. Your now is

Daniel Arias

Thanks. you that U.S. on expect on takes channel on the puts Rob, side. you were more little you and order bit side there? investment initially, maximize it about opportunity? if your requirements have guys. EUROIMMUN, What's in and view on afternoon, comment to just I talk you Good the you can the the market could infrastructure the was than needs thinking think, more a

just, I you yeah, market months? do that the can next still are So, XX feeling overall, you the that and there about is guess, in the then And then how what of portion case?

Robert F. Friel

So, well think, very Jamey EUROIMMUN as I the in again. did mentioned, U.S.

quarter they U.S. they've all areas. I year, it first least just did the across the Europe, think through exceeded at had XXXX. back the But if from in double China, you up all now another half what were of digits. step key EUROIMMUN, geographic strong

we think continue U.S., I in add tests as to specifically, think I approval. FDA we receive

the I and in to business, larger with to second we added of menu, labs. the additional about the particularly expansion assays reference think we're see seven quarter, our continuing

think received but I channel, going probably the to more the growth out the from partly adding getting to there, significant it's the what's the products getting is approval So, new FDA. drive it's some

globally, is EUROIMMUN antigens. and the probably our have, to largest and think specificity, at which tests recombinant we technology produce antibodies now, best menu of the BIOCHIP look you of being when the excellent I capabilities by at both right autoimmunity, least and driven

the therefore, work to not them. but only assays, attract specific also or can So KOLs produce they they very sensitive with very

So out be and to I the train continue PerkinElmer EUROIMMUN vice we to products build the continue the to And force that'll versa. think to on menu. continue sales approach the

do I products the huge other you just and market. that don't So, approved to a know on investment out required than there's get

Daniel Arias

Jamey, acceleration expansion to here the XX to some to still year, helpful. of get good on some your bps from back half outlook the Yeah, It you. That's margin XX the XQ. sequential targets. Thank improvements obviously for require maybe bps the okay. in half does back

you on mix back comment the that just the you're do order in that give how in of and sort confidence the half? the thinking So to elements can about you

James M. Mock

extra fourth Yeah, I in think mostly Dan. it's around some the quarter, volume

margin So expect it EUROIMMUN of as mixing some a as expansion. quarter third both as volume leverage EUROIMMUN, fourth there. then the the in amount And in the in solid for quarter will it's primarily revenue be uptick well we

Operator

question of Ross Thank from Evercore the Muken comes of ISI. line next you. And our

is line now Your open.

Ross Muken

Congrats, guys, great quarter. Hey. on a

Robert F. Friel

Thank you.

Ross Muken

So talk little bit maybe thinking China. just about a you're how about

pretty You varied there given the some recent have now that obviously markets. a are a number different business of of in moves

are Given as all And thinking capital view equipment maybe for the noise, the on as on of in well third tariff you your how whole? about uncertainty? sort any as sort in side of a base, market the that your manufacturing of any potential general, quarter just kind of

Robert F. Friel

there, a So, continues the second as the first think well so take potential in us. let growth I out up one me some perform track a to are sort you opportunity. of quarter. all, headwinds again there strong feel out, we And double time. It at was for point continuing China we're of to digits But it

of So we requires it's can I'd on we huge that's think little for all, now right absorb less, $X on extent bit of play, million of something probably think say, first or to mean, headwind and I either side, I or a in not It's a it based productivity us. pricing. state the the tariff

I think get that. we can

there's look in right come the China. and a in way, our China see would products When I used we today you chain. now from other So virtually supply no significant the don't that's say, issue, at mostly into from U.S. produced tariffs diagnostic that product as and coming

either Our Germany. Diagnostics from from products come from three sources: they made locally; Finland; they're come or come they

of see there. So don't much risk we a

million is goes we ability into that of our $XX DAS at On million probably to looked And from U.S. side, production. that China. we've there to the product $XX think move

place nine quickly, to Some in starting move probably us of that. to some take relatively we're it to we that would six put do months, us contingency and would allow other can plans

relatively to period that I probably any We some nine do some think in right haven't cases a quickly, now, in but of we cases short sort months. Like could of relatively pulled time. we in six said triggers

Ross Muken

a And color some sort yeah, us and regionally on maybe a Perten, of pretty helpful. great what food dynamics think sounded the since and had food? maybe on quarter. That's performance is asset. good give Maybe you've really applied the it applied that you like, little bought just there had and I bias

Robert F. Friel

digits. digits. a low- America you was would said food to the was single for that at as would So up up in was Europe more if was good in quarter digits strong. of in I well. sort say you North us. It I it was look and applied Asia, high-single That say mid-single

timing. I think that's somewhat

us. get I think food industrial sort for will looked probably us, digits, the if good think to the mid-single but first tracking the end you year of high it for single is through the half by of we digits. And was also

have basis hundred move quarter, to digits. sort perspective. things these the relative points. think sort couple a last are of couple And of us in the of we think was of that side our for us there can It at in up down I I we it indicated when end bucks from of pretty that sort the of million X% think a high-single percentage of out can geographic look broad-based was some for was and on of sub-XX% revenue, concern a second were timing. if industrial I as quarter recall little and of you Industrial a sort quarter markets drive you was

year-to-date, industrial mid-single. tracking of we're so now the at if you And sort look

Operator

Tycho comes our the from And of of next line JPMorgan. Thank you. question Peterson

is line open. now Your

Tycho W. Peterson

the heard this that Hey, follow light at thanks. also peers. want because quarter. bit pull-forward to what think, We've looks up Actually I And no asked I about on little from There revenue the to, we've guide a expecting been comment. relative was dynamic China a least. few XQ

Robert F. Friel

I think I I think when mean, the I China. think looking don't back I it's revenue. anything are through. Tycho. given pull look prudent conservative a in side, see issues I don't No, the some we're we think I that in revenue And think the the mean, maybe little just to expectations prudent I particularly there. in be somewhat in to so, half, I think swirling at our And the around relative to China side of out

Tycho W. Peterson

the Okay. investment for side, I want on to And to a then go minute. back EUROIMMUN

XXX that talked guess XXX Can the And had comment really that I that, driving think, is the reagents, about in where in You I you what's on if of hiring XX% process? need you previously, to there? engineers. are business conference

Robert F. Friel

Yeah.

at the to growth that annual I engineer the So any say the would is generally Siemens period. given conversation company of the think on in basis. has XX-month XXX an hiring XXX that's in that I probably historically, the I And the experienced context you the was they're if look hiring what mean, discussions.

like into as as revenue, are a work R&D. in investment been, percentage tried they've workforce the R&D at said, of if be sort historical I area look would I R&D So track but the the engineers I there high grown of most to some salespeople, record say think, going based. revenue. keep at of been to mean, of it's can the in least sort mid investment to model of they've with growing company increased the is that and teens, I you It the their has and R&D constant

And you're you're taking at XX%. up R&D growing so if your XX%,

really driving what's the that's so And of engineers. hiring the

Operator

from of Deutsche Thank comes you. Bank. the Leonard Dan of And our question next line

Your now open. line is

Dan Leonard

genetic an you're testing it update on Is specifically launched portion PerkinElmer ago? the just Thank a that genomics business? you. how Can year with doing you offer you

Robert F. Friel

Yeah.

of or say good on would see course, business. base. testing grew a XXX%, of to it's very genomics uptake well the continue I of we but, in excess It grows low off So

biotech help in as with interpretive would with organizations to I also to to so here sort consistent expanding in say, turnarounds diseases. partner and it's on, but their we treat has say faster I companies the discussed states one, of continuing our capabilities. we fundamentally them been we're the in seeing nice the And work quest testing, focused confirmatory opportunities strategy would U.S. provide with other previously, also to to, And our rare to with pharma partnerships

we what five expect lot seeing we're uptake NovaSeqs of to be probably in in to significant in September the fact, So volume here. a handle put And another opportunity. we'll

Dan Leonard

further helpful. product had implications Okay. And elaborate product beyond well just Can that a question. you with I QSights? another the up, strategic being a progress launch. as that follow That's know for on some new you then

Robert F. Friel

new little the mentioned a products. discussion say bit would I around in So I

I process think largely in DAS the out that the would Diagnostics with maybe I in side seeing to other there expand And reagents. sort of applications. into set approved we're we're the our hope side, say FDA traction good food on on of areas. over getting that of time the we just

seen we've really overall going is you'll some get reagents FDA on approval it's while very Diagnostics expand say significant we be pleased there, would And into could on think it the I until when and other to the side. increase platform But nice with we're performance – a so ramp-up our more the see areas. to

Operator

Thank you. And the Cowen. our of of Schenkel line Doug comes from next question

Your line is now open.

Doug Schenkel

start. have just taking for in to have a question. Diagnostics Good EUROIMMUN? afternoon. my clarification Chris was organic quick actually Thanks follow-up. What a Hey. QX for I This excluding growth I is today. Doug revenue on question

Robert F. Friel

XX%.

Doug Schenkel

or you just noted mid-teens for that bit Specifically categories synergies longer-term given on and commentary? growth should testing EUROIMMUN, expectations we of just what ahead sustainable a revenue more a your then I think believe were upside? provide And generating Okay. lastly, success in now is this XXXX rate Can detail early EUROIMMUN. geographies to with are beyond? And question, you

Robert F. Friel

related really probably relative would categories. put dollars future say I'd way And have So those we're I to running necessarily revenue the I will think the revenue that we three the into the describe those to synergies. that is I not but synergies would would sort of and was say revenue comment projects

product I one of new say would probably sort or really new market first around opportunities. The

And so our instrument. an example in of be there putting we're process would assays on some their of the

about example that. we've new both an bench-top combining us, that capabilities neurological And we're up assays makes for from a chemiluminescent excited where and new that of up some the got market number open so of a sort those So combining EUROIMMUN, PerkinElmer we're to course, instrument be we're of would with instances opens market of a opportunities.

I capability. it's area, of and would second say, sort where more cost The

and our both start addition reducing antibodies think, quality. will we've DX, opportunities So about, I in producing is development our which costs, DAS to going EUROIMMUN, product expanding across and as to we talked think improve

We're EUROIMMUN developing about antigens. and And menu area, sort prepared the I the has a emerging say this flow channel sort then lateral third infectious for that my and would Tulip distribution alluded a of second market lateral in in technology disease the And category. flow markets, to if and a I so in areas, that's emerging a think has of the comments. you

synergies seeing also capabilities I thought. comment respective was the So more quicker of And to projects their opportunities those anyway the companies. would seeing than my drive advance we're we're say really we across two

our to would continuing and to hold with XXXX or going off we on I XXXX at or XXXX point giving say to expand XXXX. regard EUROIMMUN get around any with confidence discussion I'm through comment second XXXX. probably this Your until into around guidance

Operator

Bank de you. And America from comes of Bruin the question our Thank line next Derik of Lynch. of Merrill

is Your open. line now

Michael Ryskin

Real is right? on out question. a In for amount. million to This taking there $XX that an at called the XQ, million Mike you Derik. Thanks was million is the around in XQ, question. Coming $XX Ryskin somewhere out that EUROIMMUN Thanks. $XX about follow-up quick, just for on

Robert F. Friel

That's about right, yeah.

Michael Ryskin

or or in pharma year, on the life then be Just terms which now for And that's broader that little hand, XXXX, least the also surprise instruments, forward. out your it upside beat. that at lot raised Are XX% a XQ, came you the outlook in your carried of then comment more X%, little segment, you but and in I more bullish? of and the second on the there end DAS anything can changed your the sciences, to mean from in in strength, X% outlook for particular DAS or already of Is where that's at know the for bulky. of a much of either a bit the looking half of print, Thanks. half on you markets applied one first the how the have the bit carries both I demand? in come comp easier any Okay. given the the an just numbers feeling

or your half? So changed second has how for is how the your outlook –

Robert F. Friel

is say, been environment, now it's the I and think would our about into the mentioned, you macroeconomic I first it as back. assumption if robust continues right No, of sort a half, fairly

know So, I I anticipating wouldn't say we're same anticipating don't any the at that deceleration. a we're time, acceleration,

the market similar we're in continuing So, saw assuming back to we to conditions what first. half

Operator

line Meehan Jack Barclays. next And the comes you. our of of Thank question from

open. now Your line is

Jack Meehan

Thanks. Hi. afternoon. Good

Robert F. Friel

afternoon. Good

Jack Meehan

impressed you of around there? segment biopharma, with what about? the elaborate Could some the Discovery Rob, couple accelerate some of I the new within commentary the is or last you products improvement the just on it's the to driving seemed funding environment was that quarters. think of Whether talked you

Robert F. Friel

as mentioned say goes of across a little and bit I've Well, sort – but things. it would really before, a number I of

think First of of better. all, global structure. account We're I we're sort getting executing the

sales the complete is selling force think better at the I getting solutions.

better category of and sort sort of I around to customers, think relative well I of the so a combination execution. OneSource is our working there's think Informatics

around category there's innovations. products I a new think and

refresh of the a think be in a you significant area, have of lot of of sales of to both And a start do we virtually the number step-up the across you applied high of there. until can lot I strong probably markets, growth. our these of So, instruments content see vivo, And time more we to platforms clearly, attributed saw did in associated imaging XXXX. a technologies, we and saw ramp-up. And in then a lag again, as fairly all appreciate, nice in that the sort

benefits are a sales a to think carry the strong think into robust leading think, XXXX, I particularly on that's of we execution force, in I DAS. growth, markets the with, through what's very are and lot XXXX end side of and combined to the saw starting I better product So, initially and

Jack Meehan

as revenue, so given the more the better I what just down little I the was on than it top looking for. Great. like of follow-up, a And primary to than to modestly we beat looked were drop EBIT. magnitude a driver line was guess beat just surprised margins were

might just mix you some wondering just a that either headwind Jamey if could walk and or maybe of maybe So been the quarter FX, in have factors, there? just the through

James M. Mock

Yeah, yeah.

basis EUROIMMUN, on exchange So, OM think then points. points XXX to foreign line the go The strong. we just core the there, XX walk. Jack, was of basis points that's points so there back basis we There exchange headwind was in to basis so from grew of XXX basis XX actually foreign and points and grew XX pretty

basis headwind, margin had points basis the FX as pretty it saw of grew XXX points, XXX well We core so basis grew line pretty on being felt we another we the there strong. EUROIMMUN also And about about positive. points, and gross XX

Robert F. Friel

Yeah.

So to up optimism I basis appreciate the points. XXX but gross perform margins our and saw ability with convert, like we

little R&D flow-through. felt were we So good a bit pretty the we on through little operating the because expenses, about higher. on fundamentally the a that lost side, particularly And line operating

Operator

And Thank Cleveland Steve of next line question from Willoughby comes you. our the Research. of

now Your line is open.

Steve Barr Willoughby

of questions for have evening. Good just couple I a Hi. you.

versus environment the Rob, robust done again, the the we've the organic continue. and experienced first about in to talked you've a First, first assuming macro I year you growth that what half in you're half guess just of pretty thinking here about back half

to and third what organic explain I guess to the XX% quarter it one time from down probably this similar So, on, is quarter growth implied. me quarter around is could think that guidance you if X% for here fourth the going maybe more for I in

Just there. I a wondering have large why deceleration follow-up And as such well. the then

Robert F. Friel

X% our I around core. the it's just think One what more the the potential headwinds, back. in by the bit it's would we'll do we got way, with prudent numbers, then I those and And say some X% Yeah, is, one other comp it's think even given fundamentally on is, a – swirling – we've that – with two. little difficult

our EUROIMMUN three to years, X% as will And course, of it go So gets organic we about last growth then, of to top the from sort on X%. us add of you think if that, X%. X% to

possibility think I pleased let on number. So, we're that won't beating that. a say what pretty is, will I constraint And our with of that we be

Steve Barr Willoughby

Jamey on $XX much. timing Vanadis, from more with Thanks something question the confirming in in past, said you And guidance. just you then that the are so revenue year? one still on million for then this And Okay. expecting

Robert F. Friel

think million probably little I $XX No, a is heavy.

$XX think $XX it's million sort than I these But tenders. of calibrated it and take because it our the And to labs. of $X to validated is of think said what to had but closer again going I we fact within think more get the $X million, probably to the is to the anticipation in of it's timing while million again the million a past I is we'll sort see. it's

And of the reagent latter not of XXXX. early the until year really going lot the to part or you're flow a so see

Steve Barr Willoughby

right thinking Perfect. you way then, kind guidance, one beat a about just of bridge basically previous you incremental being offset just headwind, new for that the between on Jamey, lower FX by to as I'm and earnings here, then and guidance, Okay. is think tax things? XQ rate about And flow the an the the guidance through the is that

James M. Mock

was tax beat then $X.XX from it from Yes, Steve. right, and exactly and $X.XX $X.XX That's a foreign exchange. headwind

it. You got

Steve Barr Willoughby

Perfect. Thanks much. so

Operator

Thank Goldman you. line of from Patrick from comes Sachs. Donnelly question And our the next

is line now Your open.

Patrick Donnelly

number just factors services for drive maybe on in you there, look the number trending innings year, the the million upside first, key genetic revenue of at $XX one right When clearly Great. to are for early what's the there? you're year you levers well the testing know this Great. then And Thanks. what Rob, seeing? XXXX. to I reaffirmed

Robert F. Friel

end say the what is said. year the is sort would I that XX maybe we're this So hopefully. of I X to probably We said think number tracking we higher for probably of and XX-ish to

throughput them to as interpretive to more areas, our putting process little a bit a from of And as fact differentiating this on levers the I sort even in good. is of the I about talked bit September. the barrier to there. standpoint. I of the so Obviously get mentioned, the more NovaSeqs sort the also past. I I are But putting opportunities time enabled samples an very on volume we're sort a mean, in of side interpretive sequencing get we think the I planning they biggest take particularly we is faster we're of right pharma probably very again up I the probably sort good But to think things, little probably mentioned now more can probably on be two sort I that mean, across and that us what's continue the that's five in out running. of software in see think in I we've area mentioned, and think all

a First differentiating of enzymes. of genes all all, provide specific our ability and at okay, to sort us lot of the level first of mutation, but also to want the really for say, is the genetic and same of quantifying of both analysis indentified pharma proteins (XX:XX) sequence companies desire time that to

samples is blood that. basically is the the because cards, So which again only from run can spot We're differentiated. the collect we can drive that's And NGS interesting. one company other and that

we're demand to I as few So And labs companies. do of think whole compared exomes. is clearly as into other of plays that's And genome our more one and a sequencing clinical the that also thing this the seeing driving we're pharma the genome can panels in is toward trend the strength lot whole test.

and So opportunity invest sort be to build to I of think there's this a of going to lot business. continue

Patrick Donnelly

just very kind strong. It there, helpful. page markets better one very quick jumps terms That's there. others? growth jump Europe, anything of of off Thanks. through growth on than And just the talk in a out with doing double-digit you then double-digit Can

James M. Mock

them, Yeah, Patrick. of a few

what strong Diagnostics reproductive for out mid-teens here. is us segment was health jumps whole the at think up I was think to So quite least and me I

one So, players. reproductive big, stronger the was health in of particular

Robert F. Friel

across fairly broad-based. I you say But again, when would was sort it look DAS, of,

double they So digits markets, whether it it was sciences, up applied life for was whether were both us. Europe in

Operator

Quirk Jaffray. next And of our Bill you. comes Thank Piper from the question of line

Your is now open. line

William R. Quirk

Great. Good afternoon, everybody. Thanks.

Robert F. Friel

afternoon. Good

William R. Quirk

couple questions, Rob. A

on expanding curious China, in this over So, call the update that the earnings just on programs to renewed some there's It an is? there? China, any some so screening latest interest first afternoon was what greatest suggested and newborn of off, earlier screening in

Robert F. Friel

face for birth depending declining western but it's I anywhere mid- well did actually part newborn would of whether of digits. So high-single eastern it's China the birth sort we're the in from in the rates. part us to say or declines seeing on rate China of again, well

then some talked decline That's you some opportunity Now to are the offset, past in we in being that menu, zodiac imagine, that do penetration so expanding the clearly is putting various by of sort of can we've good areas. of of see that sort increase about in economic as as birthrate. also and sort the impacts but there's sign

So large screening, would suggest the see, newborn as far you'll now data increased think that gets right Chinese as of our screened. I portion a

babies. so I that to there's huge of don't know So, opportunity again, more a screen sort

the U.S. we're the I opportunity is it's menu And a of mean, seeing side. even if really across number on right in only you think at China. that now, I regions, the not look interesting.

expand the You to continue of panel put out. know to continues of see opportunity continues panel, us recommended screening RUSP you the is to fairly Even uniform and there. significant menu expand nice of the within for that provide sort expansion the to that sort the which HHS U.S.,

William R. Quirk

Europe and this XXXX? that. Just wanting with in to to you adjustments to additional tenders? behind some Thanks. of get trying up Rob, to that the got because XX labs, limitation timing it. secondly, the is Thanks And reason broader the of do have you continue color. system to the XX Vanadis, anything Does there, that limiting for color the XXXX, here or that systems me, Okay, behind some terms make excuse in of evaluate before on then open in in

Robert F. Friel

other these to systems, because of think take actually importantly and I a it, probably with installed some the again it's get Yeah, validated. time is both. of of in sort mind to keep more sort starting just bit will a we're of sort But little thing

somewhat factors And get make the half. combination to to believe be think them sort in sure they're so of well. same into we're And to customers And us back sort led systems. the relative time, conservative the volume some production running of to the that key up and the these we want of at of those I ramping

Operator

Couillard line And comes Brandon from Thank Jefferies question next our of the Financial. you. of

is line now Your open.

Brandon Couillard

Good afternoon. Thanks.

there and the EPS Just then Jamey, a AR year, maybe any for EUROIMMUN-related? pretty quick one benefit onetime of And didn't you. for capital, down change there free Was came looks inventories expectations substantially flow of like working the it quarter-over-quarter. in terms despite bump you to sort cash

could speak to If just you that.

James M. Mock

cash, say first only I first with I'd of and the my chain. if Brandon, mean, at doing Yeah, the is we're you changes is Sure. quarter the half the the of versus I prepared well around therefore in this couple the remarks first as supply year, this look regard as no years different last in to and always half. second this are what half half quarter we later the quarter, what around mentioned in affected particular. that the And

original of a in and being kind center target. moves, somewhat production half new to get two our distribution that So second we to and normalizing strategy, the anticipate able

second moves question year these increase flow our your didn't So free because answer our to guidance for need we see. of of the we cash and the target, to end

that of both this year, next of going still we'll settle beginning them into XXXX. half feel might Some generate and good of of this might very a in year, but out we some the cash settle the out in lot second

Brandon Couillard

you. Got you. It's helpful. Thank

Operator

would this now call closing Rob Thank showing I at you. am I turn to the to like remarks. further back no Friel for time. questions

Robert F. Friel

Great.

PerkinElmer. first your in questions interest continued So, of your thanks all, and for

look drive shareholders, customers, while innovating employees. So value world we continuing to for and creating greater mission to even our of forward a healthier for our

and So everyone has thanks hope evening. great I again, a

Operator

you today's may day. This and great in Ladies does and thank Everyone, disconnect. program, have for conclude you gentlemen, all participating the a conference.

Revvity (RVTY) 1 Aug 182018 Q2 Earnings call transcript